FDA approvals continue the upward trend noted in the first quarter, with the registration of the first deuterated compound, a new small-molecule drug for amyotrophic lateral sclerosis (ALS) and accelerated approval of Imfinzi, a checkpoint inhibitor for use in bladder cancer. A slew of drugs gained breakthrough therapy designation (Supplementary Table 1). The first approved gene therapy Glybera was axed for economic reasons; two biosimilars ran into trouble at the FDA.
Author information
Authors and Affiliations
Supplementary information
Supplementary Table 1
Supplementary Table 1 (XLSX 10 kb)
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 2Q17. Nat Biotechnol 35, 703 (2017). https://doi.org/10.1038/nbt.3941
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3941
